{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:14:20Z","timestamp":1791209660372,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/ico.0b013e3181c325b2","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:50:33Z","timestamp":1271119833000},"page":"618-621","source":"Crossref","is-referenced-by-count":296,"title":["Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications"],"prefix":"10.1097","volume":"29","author":[{"given":"Robert D","family":"Fechtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Budenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette A","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Jasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210204","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome.","volume":"118","author":"Moss","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R2-5-20210204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archopht.122.4.532","article-title":"Prevalence of open-angle glaucoma among adults in the United States.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R3-5-20210204","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ico.0000220776.93852.d9","article-title":"Incidence and prevalence of glaucoma in severe ocular surface disease.","volume":"25","author":"Tsai","year":"2006","journal-title":"Cornea"},{"key":"R4-5-20210204","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients.","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"key":"R5-5-20210204","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R6-5-20210204","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0939-6411(01)00246-6","article-title":"Ocular tolerance of preservatives and alternatives.","volume":"53","author":"Furrer","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"R7-5-20210204","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02849799","article-title":"Evaluation of the comfort of Alphagan P compared to Alphagan in irritated eyes.","volume":"20","author":"Mundorf","year":"2003","journal-title":"Adv Ther"},{"key":"R8-5-20210204","first-page":"1436","article-title":"Evaluating the functional impact of dry eye: the ocular surface disease index [abstract].","volume":"31","author":"Walt","year":"1997","journal-title":"Drug Inf J"},{"key":"R9-5-20210204","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index.","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R10-5-20210204","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients.","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R11-5-20210204","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R12-5-20210204","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R13-5-20210204","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(14)71688-5","article-title":"Prevalence of dry eye among the elderly.","volume":"124","author":"Schein","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R14-5-20210204","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00061198-200312000-00008","article-title":"Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride.","volume":"12","author":"Ishibashi","year":"2003","journal-title":"J Glaucoma"},{"key":"R15-5-20210204","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00055735-199604000-00014","article-title":"Side effects of antiglaucomatous drugs on the ocular surface.","volume":"7","author":"Baudouin","year":"1996","journal-title":"Curr Opin Ophthalmol"},{"key":"R16-5-20210204","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1167\/iovs.04-1426","article-title":"Decreased corneal sensitivity in patients with dry eye.","volume":"46","author":"Bourcier","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-5-20210204","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","article-title":"Compliance barriers in glaucoma: a systematic classification.","volume":"12","author":"Tsai","year":"2003","journal-title":"J Glaucoma"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201006000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:31Z","timestamp":1786040431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201006000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181c325b2","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}